Tirzepatide for weight loss in early breast cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with early-stage (stage I, II, or III) hormone receptor-positive, HER2-negative breast cancer.
- You have completed your main breast cancer treatments (surgery, chemotherapy, radiation) with the goal of curing the cancer.
- Your BMI is 30 or higher, OR your BMI is 27 or higher and you also have a weight-related condition like high blood pressure, type 2 diabetes, or sleep apnea.
- You are able to be active and care for yourself (ECOG performance status 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a medication (GLP1/GIP-receptor agonist) can boost the immune system to fight breast cancer before surgery. It is for postmenopausal women with early-stage, estrogen-receptor-positive, HER2-negative breast cancer who have a BMI of 27 or higher (with weight-related health issues) or a BMI of 30 or higher.
This trial tests if tirzepatide, a weight-loss medication, can help postmenopausal women with hormone-positive breast cancer who have obesity. It aims to improve health outcomes after completing cancer treatment.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This study tests whether the weight-loss drug tirzepatide (Mounjaro) can help prevent breast cancer from coming back in people who are overweight and have a sign of leftover cancer cells in their blood (called MRD-positive). You must have already finished at least one year of hormone therapy for early-stage breast cancer.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.